Potential Applications and Risks of Supranutritional Selenium Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Critical Review
Open Access
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most prevalent chronic diseases in the world, lacking specific pharmacological interventions or well-established treatments. MASLD involves intricate pathological mechanisms characterized by oxidative stress and robust inflammatory responses. Selenium, an essential trace element, plays a critical role in antioxidation, regulation of inflammation, anticancer activity, and so on. Recent studies have reported that supplementation with selenium could alleviate MASLD and associated hepatic disorders, while excessive consumption may result in insulin resistance or even selenosis. Therefore, supranutritional selenium supplementation can be more suitable for the therapy and prevention of MASLD. This paper comprehensively reviews research about selenium and MASLD to highlight the potential applications and risks of supranutritional selenium supplementation in MASLD, following three steps: conducting a search, reviewing research articles and reviews, and discussing results. The keywords for the search include but are not limited to selenium, MASLD, supranutritional, hepatic diseases, selenoproteions, and selenium nanoparticles (SeNPs). We have reached the following conclusions: supranutritional selenium supplementation exhibits promising potential as a strategy to treat MASLD, but there are still some risks, depending on the dose and form of selenium; evaluating MASLD severity and selenium nutritional status accurately, as well as supplementing with superior forms of selenium (e.g., organic selenium and SeNPs), can further ensure the safety and efficacy of selenium supplementation. However, relationships between selenium homeostasis disorders and the occurrence and development of MASLD have not been fully elucidated. Methods for comprehensively assessing selenium status and mechanisms of selenosis require further investigation and research.Keywords
Funding Information
- National Key R&D Program of China (2022YFD2101003, 32172772, B18053, 2024SFQZX014, 22JCZXJC00020)
- National Natural Science Foundation of China (2022YFD2101003, 32172772, B18053, 2024SFQZX014, 22JCZXJC00020)
- 111 Project from the Education Ministry of China (2022YFD2101003, 32172772, B18053, 2024SFQZX014, 22JCZXJC00020)
- National Innovation Demonstration Zone (Zaozhuang) for Sustainable Development of China (2022YFD2101003, 32172772, B18053, 2024SFQZX014, 22JCZXJC00020)
- Beijing–Tianjin–Hebei Basic Research Cooperation Project (2022YFD2101003, 32172772, B18053, 2024SFQZX014, 22JCZXJC00020)
This publication has 152 references indexed in Scilit:
- Biomimetic Selenium‐Nanocomposites Alleviate MASH by Modulating Lipid and Iron HomeostasisAdvanced Healthcare Materials, 2025
- SELENOI Functions as a Key Modulator of Ferroptosis Pathway in Colitis and Colorectal CancerAdvanced Science, 2024
- Ameliorative effects of supranutritional selenium on TLR‐4‐NF‐kB‐TNF‐α‐mediated hepatic oxidative injury and inflammation in goats fed high concentrate dietFood Science & Nutrition, 2022
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of diseaseHepatology, 2017
- The origin of fibrogenic myofibroblasts in fibrotic liverHepatology, 2016
- Subacute toxicity of nano-selenium compared to other selenium species in miceEnvironmental Toxicology and Chemistry, 2012
- Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinomaHepatology, 2011
- Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits HypothesisHepatology, 2010
- Biological effects of a nano red elemental seleniumBioFactors, 2001
- Long-term Selenium ExposureArchives of internal medicine (1960), 1979